European Association for the Study of the Liver 2017: Update From Amsterdam
Thursday, May 4, 2017
1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HCV infection. This webinar highlights key data presented at EASL 2017, the International Liver Congress in Amsterdam, Netherlands, held from April 19 to April 23. The most up-to-date information on investigational direct-acting antiviral agents, current recommendations for managing hepatitis C virus (HCV) infection, and other important information that may impact your clinical practice are discussed.
At the conclusion of this webinar, participants will be able to:
- Describe recent data from important studies in hepatology, infectious diseases, and pharmacology
- List investigational direct-acting antiviral agents currently in development
- Describe current approaches to the management of hepatitis C virus (HCV) infection in HIV/HCV coinfection
Who Should Attend
This webinar is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, May 3, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-17-051-L01-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.